HIV care in Yangon, Myanmar; successes, challenges and implications for policy

Table 2 Comparison between patients who had died or who were alive on ART at the end of the study period

Variable	All n = 2643	Died n = 151^a	Alive on ART n = 2381^a	p^
Age	37 (31–44)	40 (33–45)	37 (31–44)	0.001
Gender (% male)	1494 (57%)	96 (64%)	1327 (56%)	0.06
Unemployed	917 (35%)	64 (42%)	814 (34%)	0.04
Living in a different region^b	526 (20%)	43 (30%)	462 (20%)	0.005
CD4 + count at registration (cells/mm³)	169 (59–328)	45 (23–127)	183 (65–337)	<0.001
WHO stage at registration	3 (3–3)	4 (3–4)	3 (2–3)	0.0001
On treatment for tuberculosis	1124 (43%)	99 (66%)	971 (41%)	<0.001
Isoniazid prophylaxis therapy^c	21 (0.8%)	0	20 (0.8%)	0.26
Co-trimoxazole prophylaxis therapy^d	2125 (81%)	136 (93%)	1904 (80%)	<0.001

All numbers represent median and interquartile range or absolute number (percentage)
^ Comparison between survivors and those that died using Kruskal–Wallis or Chi squared test
^aDoes not include the 111 patients in the cohort lost to follow up
^b75 patients did not have an address recorded; 6 patients who died and 69 still alive
^cOne patient lost to follow up
^d2627 (99%) had data regarding co-trimoxazole prescription

ISSN: 1742-6405